Tag: multiple sclerosis

Vascular Comorbidity in MS Linked to Atrophy, Functional Decline

Vascular comorbidities, including diabetes and hypertension, are linked to significantly lower measures of neurologic function in people with multiple sclerosis (MS) vs patients without these...

COVID-19 Risks No Higher in Patients With Multiple Sclerosis

The risk of severe outcomes from COVID-19 infection in patients with multiple sclerosis seems to align with that seen in the general population, new US...

Serum NfL May Flag Subclinical Disease in Pregnant MS Patients

Among women with multiple sclerosis (MS), levels of serum neurofilament light (sNfL) are higher during pregnancy and the postpartum period. The increase in sNfL is...

Increased Risk of Severe COVID With Anti-B-Cell MS Drugs?

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Concerns are being raised over an increased risk of severe COVID-19...

Prior Autoimmunity Does Not Predict Adverse Events

There is no evidence to support the idea that previous autoimmunity before or after alemtuzumab treatment predicts subsequent rare but serious and possibly life-threatening autoimmune...

Lower Rituximab Dose as Effective, Safer in MS

Further data suggesting that a lower dose of rituximab seems to offer similar effectiveness with a better safety profile than higher doses commonly used have...

Researchers Identify Five Cognitive Phenotypes in MS

Researchers have identified five cognitive phenotypes among patients with multiple sclerosis (MS). The lead researcher described the clinical characteristics and MRI findings unique to each...

Masitinib Impresses in ‘Nonactive’ Progressive MS

The investigational drug, masitinib (AB Science), which has a completely new mechanism of action for multiple sclerosis (MS), has shown a positive result in slowing...

Multiple Sclerosis Prodrome Holds Promise of Earlier Diagnosis

“It is time that the prodromal phase of multiple sclerosis is formally recognized.” That was the conclusion of Helen Tremlett, PhD, delivering the opening plenary...

Smoking Increases Risk of High Plasma NfL Levels in MS

A new study has found that patients with multiple sclerosis (MS) who smoke cigarettes regularly have an increased risk of higher plasma neurofilament light levels...

Lessons for Patients With MS and COVID-19

Two important lessons about managing patients with multiple sclerosis (MS) and COVID-19 have emerged from a hospital clinic in Madrid that managed COVID-infected patients with...

NfL Blood Biomarker Captures Suboptimal Treatment Response in MS

Measuring serum levels of neurofilament light chain (NfL) is an effective way of detecting disease activity and the need to optimize treatment in patients with...

App for MS Aims to Capture Elusive Signals of Progression

Investigators in Switzerland are testing an application for smartphones that they hope will elucidate subtle signs of disease progression in multiple sclerosis (MS)—beyond what standard...

Cardiovascular Risk Factors Linked to Brain Atrophy in MS

Dr Raffaello Bonacchi The presence of cardiovascular risk factors in patients with multiple sclerosis (MS) is associated with a greater degree of brain atrophy even...

In MS, Serious AEs More Common in Rituximab vs Ocrelizumab

Serious side effects make up the majority of adverse effects of rituximab and ocrelizumab in patients with multiple sclerosis (MS), a new postmarketing analysis finds,...

TNF Inhibitors Linked to Inflammatory CNS Events

Use of tumor necrosis factor (TNF) inhibitors in patients with autoimmune diseases may increase risk for inflammatory central nervous system (CNS) outcomes, new research suggests...

FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS

The US Food and Drug Administration (FDA) has approved ofatumumab injection (Kesimpta, Novartis) for the treatment of adults with relapsing forms of multiple sclerosis, including...

Ofatumumab Phase 3 Multiple Sclerosis Trials Published

Two phase 3 clinical trials showing impressive results with the new subcutaneously-delivered, B-cell depleting multiple sclerosis anti-CD20 mononclonal antibody ofatumumab (Arzerra) have now been published...

CHMP Backs Bupivacaine/Meloxicam (Zynrelef) for Postop Pain

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the fixed-dose combination of bupivacaine and...

Ofatumumab Shows High Elimination of Disease Activity in MS

With ofatumumab (Arzerra, Novartis), a fully human anti-CD20 monoclonal antibody, there is a greater likelihood of there being no evidence of disease activity (NEDA-3) for...

High Levels of Air Pollution Linked to Increased MS Risk

Air pollution may be another environmental risk factor for developing multiple sclerosis (MS), new research suggests. A large cohort study of almost 550,000 individuals living...

Blood Test Might Predict Worsening MS

By Serena Gordon HealthDay Reporter THURSDAY, May 21, 2020 (HealthDay News) — A new blood test might help doctors predict whether someone’s...

Depression Linked to Neuro Dysfunction, Brain Lesions in MS

Depression is associated with decreased neurologic function and new brain lesions in patients with multiple sclerosis (MS), new research suggests. In an observational study of...

Reassuring’ Study Examines COVID-19 Risk in MS

What your doctor is reading on Medscape.com: MAY 08, 2020 — Multiplesclerosis (MS) may not be one of the more serious comorbidities when it...

Multiple Sclerosis Tied to Increased Risk for Stroke, CVD, Death

Multiple sclerosis (MS) is associated with an increased risk for acute coronary syndrome (ACS), stroke, and death, a finding is unexplained by traditional risk factors,...